Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) announced that on July 15, 2026, its board compensation committee granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to newly hired employees. The awards comprise non-qualified stock options for 35,750 shares and 79,050 RSUs under the 2026 Inducement Plan.
The stock options have a 10-year term and an exercise price of $29.41, equal to the common stock closing price on the grant date. Options vest 25% after one year from each employee’s start date, then monthly over 36 months. RSUs vest in four equal annual installments on July 15 from 2027–2030, subject to continued service.
Positive
- Inducement awards to new hires: 35,750 stock options and 79,050 RSUs
- Stock option exercise price set at market close on grant date: $29.41
Negative
- Potential future share dilution from 114,800 combined options and RSUs
News Explained
Granted on
Market reaction after inducement equity grants: ZBIO +3.96% in the Jul 20 session
In the Jul 20 session, ZBIO gained 3.96%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 17 | Inducement grants | Neutral | +6.5% | Employee options and RSUs were granted under Nasdaq inducement rules. |
| Jun 11 | Conference presentation | Neutral | +11.5% | Management presentation was scheduled for the H.C. Wainwright summit. |
| Jun 02 | Phase 3 clinical data | Positive | +1.6% | INDIGO met its primary and key secondary endpoints with comparable safety. |
| May 28 | BLA submission | Positive | +2.6% | The company submitted an obexelimab biologics license application to the FDA. |
| May 19 | Phase 3 results | Positive | +6.5% | INDIGO reported reduced flare risk and favorable secondary endpoint results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five selected historical events all recorded positive 24-hour reactions; neutral announcements accounted for the two divergence classifications.
Key Terms
non-qualified stock options financial
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750 shares of the Company’s common stock (“Stock Options”) and an aggregate of 79,050 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Stock Options have a ten-year term and an exercise price per share of
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
